Depression: le point sur les traitements psychopharmacologiques [Pharmacotherapy of depression: recent developments]

Details

Serval ID
serval:BIB_41BFDD9088EB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Depression: le point sur les traitements psychopharmacologiques [Pharmacotherapy of depression: recent developments]
Journal
Rev Med Suisse
Author(s)
Baumann Pierre
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
2007
Volume
3
Number
125
Pages
2079-4
Language
french
Notes
Pi 578DA - 20071017LA - freTitre original : Depression: le point sur les traitements psychopharma- cologiquesRN - 0 (Antidepressive Agents)SB - IM
17939526
Abstract
The clinical properties of the first antidepressant, imipramine, were described already 50 years ago. Almost all antidepressants are noradrenergic, serotonergic and/or dopaminergic. Pharmaceutical companies experience difficulties in the development of drugs, of which the mecanism of action is related to other neuronal systems. Recently, the dual reuptake inhibitor duloxetine, the atypical antipsychotic quetiapine, desvenlafaxine (the main metabolite of venlafaxine) were developed for the treatment of depression. The noradrenergic and dopaminergic bupropion, in combination with other antidepressants, is a promising drug for the treatment of resistant depression. Finally, agomelatine, by its effects on the receptors of melatonin and on the 5-HT2c receptor, presents a unique pharmacological profile
Keywords
Cery, Depression, drug, drug therapy, Drug Therapy,Combination, Humans, pharmacology, receptor, SITE, therapeutic use, two$, Venlafaxine
Create date
12/01/2021 17:17
Last modification date
20/01/2021 7:26
Usage data